Infections due to emerging and uncommon medically important fungal pathogens

被引:417
作者
Walsh, TJ
Groll, A
Hiemenz, J
Fleming, R
Roilides, E
Anaissie, E
机构
[1] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA
[2] Wilhelms Univ Med Ctr, Div Pediat Hematol Oncol, Munster, Germany
[3] Med Coll Georgia, Div Hematol Oncol, Augusta, GA 30912 USA
[4] Boston Univ, Med Ctr, Div Infect Dis, Boston, MA USA
[5] Univ Thessaloniki, Dept Pediat, GR-54006 Thessaloniki, Greece
[6] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
关键词
emerging pathogens; fungal infections; immunocompromised;
D O I
10.1111/j.1470-9465.2004.00839.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The emergence of less common but medically important fungal pathogens contributes to the rate of morbidity and mortality, especially in the increasingly expanding population of immunocompromised patients. These pathogens include septate filamentous fungi (e.g., Fusarium spp., Scedosporium spp., Trichoderma spp.), nonseptate Zygomycetes, the endemic dimorphic pathogen Penicillium marneffei, and non-Cryptococcus, non-Candida pathogenic yeast (e.g., Trichosporon spp.). The medical community is thus called upon to acquire an understanding of the microbiology, epidemiology and pathogenesis of these previously uncommon pathogens in order to become familiar with the options for prevention and treatment.
引用
收藏
页码:48 / 66
页数:19
相关论文
共 174 条
[1]   Antifungal susceptibilities of Paecilomyces species [J].
Aguilar, C ;
Pujol, I ;
Sala, J ;
Guarro, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1601-1604
[2]   CASE OF PHAEOHYPHOMYCOSIS CAUSED BY A NEW SPECIES OF PHIALOPHORA [J].
AJELLO, L ;
GEORG, LK ;
STEIGBIGEL, RT ;
WANG, CJK .
MYCOLOGIA, 1974, 66 (03) :490-498
[3]   THE EMERGING ROLE OF FUSARIUM INFECTIONS IN PATIENTS WITH CANCER [J].
ANAISSIE, E ;
KANTARJIAN, H ;
RO, J ;
HOPFER, R ;
ROLSTON, K ;
FAINSTEIN, V ;
BODEY, G .
MEDICINE, 1988, 67 (02) :77-83
[4]   AZOLE THERAPY FOR TRICHOSPORONOSIS - CLINICAL-EVALUATION OF 8 PATIENTS, EXPERIMENTAL-THERAPY FOR MURINE INFECTION, AND REVIEW [J].
ANAISSIE, E ;
GOKASLAN, A ;
HACHEM, R ;
RUBIN, R ;
GRIFFIN, G ;
ROBINSON, R ;
SOBEL, J ;
BODEY, G .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) :781-787
[5]  
ANAISSIE EJ, 1992, J INFECT DIS, V165, P1155, DOI 10.1093/infdis/165.6.1155
[6]   COMPARATIVE EFFICACIES OF AMPHOTERICIN-B, TRIAZOLES, AND COMBINATION OF BOTH AS EXPERIMENTAL-THERAPY FOR MURINE TRICHOSPORONOSIS [J].
ANAISSIE, EJ ;
HACHEM, R ;
KARYOTAKIS, NC ;
GOKASLAN, A ;
DIGNANI, MC ;
STEPHENS, LC ;
TINU, CK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (11) :2541-2544
[7]  
Baddley JW, 2000, J CLIN MICROBIOL, V38, P395
[8]   CUTANEOUS MUCORMYCOSIS IN A HEART-TRANSPLANT PATIENT ASSOCIATED WITH A PERIPHERAL CATHETER [J].
BARAIA, J ;
MUNOZ, P ;
DEQUIROS, JCLB ;
BOUZA, E .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (09) :813-815
[9]   CATHETER-RELATED MALASSEZIA-FURFUR FUNGEMIA IN IMMUNOCOMPROMISED PATIENTS [J].
BARBER, GR ;
BROWN, AE ;
KIEHN, TE ;
EDWARDS, FF ;
ARMSTRONG, D .
AMERICAN JOURNAL OF MEDICINE, 1993, 95 (04) :365-370
[10]  
BERENGUER J, 1989, REV INFECT DIS, V11, P890